Long noncoding RNA NNT-AS1 functions as an oncogene in breast cancer via repressing ZFP36 expression

Q.-H. Pan, Y.-H. Fan, Y.-Z. Wang, D.-M. Li, C.-E. Hu, R.-X. Li

Article ID: 4783
Vol 34, Issue 3, 2020
DOI: https://doi.org/10.23812/20-100-A-13
Received: 9 July 2020; Accepted: 9 July 2020; Available online: 9 July 2020; Issue release: 9 July 2020

Abstract

Breast cancer is one of the most common cancers in women. This study focuses on the effects of Long non-coding RNAs (lncRNAs) NNT-AS1 on breast cancer cell growth and metastasis. Fifty-six pairs of breast cancer (BC) tissues and matched paracarcinoma tissues were obtained. The BC cell lines and normal human breast cell line were employed. NNT-AS1 in BC cells was knocked down by shRNA. Cell counting kit-8 assay (CCK-8), colony formation assay, cell cycle analysis, cell apoptosis analysis, cound healing assay, Transwell assay, cioinformatics analysis, Western blot analysis and Xenograft model were used. Quantitative real-time polymerase chain reaction (qRT-PCR) assay indicated that expression of NNT-AS1 was obviously upregulated in breast cancer tissues compared with adjacent tissues (n=56). Knockdown of NNT-AS1 could attenuate breast cancer cell viability, proliferation, invasion and migration, as well as promote cell apoptosis and induce cell cycle arrest at G0/G1 phase. ZFP36 was directly combined with NNT-AS1, and silencing of ZFP36 could rescue tumor suppression role by downregulating NNT-AS1 on cell proliferation and metastasis. Knockdown of NNT-AS1 could suppress cell growth and metastasis via interacting with ZFP36 in vivo. This study demonstrated that knockdown of NNT-AS1 had tumor-suppressive effect on breast cancer progression and metastasis via interacting with ZFP36 in vitro and in vivo, which provides a new insight into the treatment and prognosis evaluation of breast cancer.


Keywords

LncRNAs;ZEP36;breast cancer;metastasis;tumor growth


References

Supporting Agencies



Copyright (c) 2020 Q.-H. Pan, Y.-H. Fan, Y.-Z. Wang, D.-M. Li, C.-E. Hu, R.-X. Li




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).